Clinical trials: Prostatic Neoplasms, Castration-Resistant
Prostate Cancer Metastatic to Bone
Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy
Radium-223 chloride is an alpha-emitting radiopharmaceutical with proven survival benefit in patients with castration-resistant prostate cancer metastatic to bone.
- Trial name
- RaRe (NCT03458559)
- Testing
- Radium-223 chloride, Rhenium-188-HEDP
- Where
- Netherlands
- Volunteers
- 402 people
- Sponsor
- Amsterdam UMC, location VUmc
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
ProsTIC Registry of Men Treated With PSMA Theranostics
This is a descriptive, observational, prospective, open-ended, registry utilising electronic data capture to collect information on the outcomes of men treated with prostate specific-membrane antigen (PSMA) theranostics.
- Trial name
- NCT04769817
- Testing
- 177Lu-PSMA
- Where
- Australia
- Volunteers
- 500 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Metastatic Castration-resistant Prostate Cancer
Phase 1 Study of ATRS-2002 in Healthy Male Adults
To access the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered ATRA-2002 against commercially available oral formulation of abiraterone acetate in healthy male adults
- Trial name
- NCT04879589
- Testing
- Abiraterone Acetate
- Volunteers
- healthy volunteers welcome
- Sponsor
- Syneos Health
Prostatic Neoplasms
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
The purpose of this study is to determine whether survival can be prolonged in patients with castration-resistant prostate cancer who receive dasatinib with docetaxel and prednisone.
- Trial name
- READY (NCT00744497)
- Testing
- Dasatinib, Docetaxel, Prednisone
- Where
- 186 sites in United States, Argentina and 23 more
- Volunteers
- 1,930 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer
Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer
This clinical study will evaluate the role of combination therapy of Provenge followed by docetaxel for patients with metastatic castration-resistant prostate cancer (CRPC, (prostate cancer that is resistant to medical or…
- Trial name
- NCT02793219
- Testing
- Sipuleucel-T, Docetaxel
- Where
- United States
- Sponsor
- The University of Texas Health Science Center, Houston
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
This phase II trial tests how well pertuzumab, trastuzumab, hyaluronidase-zzxf and enzalutamide works in treating patients with castration-resistant prostate cancer that has spread from where it first started to other places in…
- Trial name
- NCT05730712
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Prostate Cancer
Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.
This study aimed to evaluate the diagnostic performance of 18F-DCFPyL (PyL) PET/CT in subjects presenting not previously treated for castration resistant prostate cancer and showing negative or equivocal findings per…
- Trial name
- PROSTEP-002 (NCT04655365)
- Testing
- Enzalutamide capsule
- Where
- 4 sites in Canada
- Volunteers
- 30 people
- Sponsor
- CHU de Quebec-Universite Laval
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer
To evaluate whether the efficacy of the abiraterone acetate tablets (I) is comparable to that of the ZYTIGA®) by comparing the serum testosterone concentrations on Day 9 and/or Day 10 after oral administration of the two…
- Trial name
- NCT04862091
- Testing
- Abiraterone Acetate Tablets (I), ZYTIGA®
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Metastatic Progressive Castration-resistant Prostate Cancer, Metastatic Progressive Breast Cancer
Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method
The primary objective of the preliminary lead-in study is to determine whether circulating tumor cells in patients with metastatic progressive castration-resistant prostate cancer or metastatic progressive breast cancer can be…
- Trial name
- CTC-EMT (NCT02025413)
- Testing
- Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Duke University
Advanced or Metastatic Adrenocortical Carcinoma, Metastatic Castration-resistant Prostate Cancer
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
This FIH study is designed to assess the safety, tolerability, and preliminary efficacy signals of DS9051b in participants with ACC and mCRPC.
- Trial name
- NCT07189403
- Testing
- DS9051b
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 40 people
- Sponsor
- Daiichi Sankyo
Metastatic Castration-resistant Prostate Cancer
A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.
A first-in-human clinical trial to test the investigational treatment ONCT-534 in participants with metastatic castration-resistant prostate cancer.
- Trial name
- NCT05917470
- Testing
- ONCT-534
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 21 people
- Sponsor
- Oncternal Therapeutics, Inc
Metastatic Castration-resistant Prostate Cancer
Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
This is an open-label, phase 1b dose-escalation study of cabozantinib in combination with 177Lu-PSMA-617 in subjects with mCRPC.
- Trial name
- CaboLu (NCT05613894)
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Utah
Castrate-resistant Metastatic Prostate Cancer
Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer
Cabazitaxel is already approved by the Food and Drug Administration (FDA) for use in patients with advanced prostrate cancer, following docetaxel therapy.
- Trial name
- NCT01750866
- Testing
- Cabazitaxel, Prednisone, Granulocyte colony-stimulating factor (G-CSF)
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer
Assess whether the combination of ABT-888 with temozolomide (TMZ) has activity in subjects with metastatic castration resistant prostate cancer (CRPC) as reflected by the prostate-specific antigen (PSA) response.
- Trial name
- NCT01085422
- Testing
- ABT-888, temozolomide
- Volunteers
- 35 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Prostatic Cancer
Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer
This is an open label, Phase I/IIa trial of immunotherapy with CreaVax-PC as treatment in men with hormone-Refractory Metastatic Prostate Cancer.
- Trial name
- NCT01171729
- Testing
- Autologous dendritic cell
- Where
- 2 sites in South Korea
- Volunteers
- 12 people
- Sponsor
- Samsung Medical Center
Metastatic Castrate-Resistant Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer)
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
In this phase Ib/II study, participants with metastatic castration-resistant prostate cancer (mCRPC) who failed prior novel hormone therapy will be treated with XNW5004 in combination with enzalutamide.
- Trial name
- NCT06702995
- Testing
- XNW5004, enzalutamide
- Where
- 2 sites in China
- Volunteers
- 307 people
- Sponsor
- Evopoint Biosciences Inc.
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Hsp90 inhibitor STA-9090 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. This phase II trial is studying how well Hsp90 inhibitor STA-9090 works in treating patients with metastatic…
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01270880
- Testing
- Hsp90 inhibitor STA-9090, laboratory biomarker analysis, polymerase chain reaction
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Castration-Resistant Prostatic Cancer, Metastasis
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT06863272
- Testing
- Docetaxel, Ifinatamab Deruxtecan, Opevesostat
- Where
- 82 sites in United States, Argentina and 17 more
- Volunteers
- 360 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to…
- Conditions
- Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT07200830
- Testing
- Lutetium Lu 177 Vipivotide Tetraxetan, Biospecimen Collection, Patient Monitoring
- Where
- 138 sites in United States
- Volunteers
- 1,524 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Castration-resistant Prostate Cancer
Oral Calcitriol With Ketoconazole in CRPC
The aim of this study is to estimate the PSA response rate with the use of ketoconazole (400mg QD + hydrocortisone 20mg AM, 10 mg PM) among men with CRPC in whom disease has progressed despite abiraterone
- Trial name
- NCT03261336
- Testing
- Calcitriol, Ketoconazole, Hydrocortisone
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Donald Trump, MD